Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

Share Price is delayed by 15 minutes
Get Live Data
43.80    0.00 (0.00%)
Bid:
42.80
Ask:
44.80
Spread: 2.00 (4.673%)
Market Cap: £68.37m
MIG3 Live PriceLast checked at - London Stock Exchange

Intraday Maven Grwth 3 Share Chart

Statement re Offer for Subscription

22 Sep 2017 18:25

RNS Number : 6312R
Maven Income & Growth VCT 4 PLC
22 September 2017
 

Joint Announcement

 

Offer for Subscription

 

22 September 2017

The board of directors of Maven Income and Growth VCT 3 PLC ("Maven VCT 3") and Maven Income and Growth VCT 4 PLC ("Maven VCT 4") (together the "Companies" and each a "Company") are pleased to announce that they have published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription for new Ordinary Shares of 10p each in the Companies to raise, in aggregate, up to £30 million with over-allotment facilities of up to, in aggregate, a further £10 million (before issue costs) (the "Offers").

 

The Companies have also published a joint circular (the "Circular") seeking the approval of their respective shareholders for matters in connection with the Offers, each Company giving notice of a general meeting to be held on 8 November 2017 (the "General Meeting").

 

The Offers will open on 22 September 2017 and are expected to close no later than 3 April 2018 in relation to the tax year 2017/18 and on 20 April 2017 in relation to the tax year 2018/19 (unless the relevant Offer is fully subscribed by an earlier date or previously extended by the relevant board to no later than 14 September 2018).

 

Each Offer is conditional on the passing of all the resolutions at the relevant General Meeting.

Pursuant to individual offer agreements dated 22 September 2017 relating to each Offer between, among others, each relevant Company and Maven Capital Partners LLP ("Maven"), Maven, as the administrator of the Offer, will receive an offer administration fee of 2.5% of the application amount in relation to each accepted application, with reductions to the fee applying in certain cases (for instance, early applications under the Offers). Maven as the investment manager of each Company is a related party of each Company under the Listing Rules, and the payment of such a fee by the Company to Maven is a transaction to which Listing Rule 11.1.10R applies.

Further, William Nixon has expressed his intention, prior to the close of each of the Offers, to subscribe £50,000 in Maven VCT 3 and £50,000 in Maven VCT 4 under the relevant Offer. As a director of each of the Companies, William Nixon is a related party of the relevant Company under the Listing Rules and consequently each subscription is a transaction to which Listing Rule 11.1.10R applies.

Maven VCT 3 has also agreed with Maven that with effect from 1 December 2017 Maven will also be entitled to a performance incentive fee, for each six month period ending 31 May and 30 November, of an amount equal to 15% of any increase in the total return (before applying any performance incentive fee) as at the end of the relevant six month period to the total return (after accruing for the performance incentive fee payable for that period) compared to the end of the last six month period on which a performance incentive fee was paid. Payments in relation to any performance incentive fee shall not exceed £890,000 in relation to any rolling twelve month period ending on the date of the proposed payment. Maven and Maven VCT 3 have also agreed to vary the terms of a co-investment agreement (which enables employees and officers of Maven to co-invest with Maven VCT 3 in certain new and follow-on investments) with the effect that the 8% total investment limit (which applies to the investments that can be made by such employees and officers) will be reduced to 5% with effect from 1 December 2017. As Maven is a related party of Maven VCT 3 under the Listing Rules, the introduction of a performance incentive fee payable by that Company to Maven, together with the variation of the co-investment arrangements, are transactions to which Listing Rule 11.1.10R applies.

To obtain a copy of the Securities Note, private investors and financial advisers should call Maven Capital Partners LLP on 0141 306 7400. A downloadable version of the Securities Note will also be available from the each of the Company's websites: http://www.mavencp.com/migvct3 and http://www.mavencp.com/migvct4 .

 

Copies of the Prospectus and Circular are available, free of charge, from Maven Capital Partners UK LLP at Kintyre House, 205 West George Street, Glasgow G2 2LW.

 

In accordance with the Listing Rules, the Prospectus and Circular have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

www.morningstar.co.uk/uk/NSM.

 

Any enquiries in respect of the Offers should be directed to:

Maven Capital Partners UK LLP

Telephone: 0141 306 7400E-mail: enquiries@mavencp.com

Maven Capital Partners UK LLPSecretary

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRPGUWPBUPMGMP
Date   Source Headline
11th Mar 202211:35 amRNSIssue of Equity - Dividend Investment Scheme
10th Mar 202211:30 amRNSIssue of Equity
10th Mar 202211:20 amRNSStatement re Dividend Investment Scheme
7th Mar 20226:32 pmRNSAnnual Financial Report
22nd Feb 20222:27 pmRNSTransaction in Own Shares
18th Feb 20225:48 pmRNSIssue of Equity - Replacement Announcement
7th Feb 20221:53 pmRNSDirector/PDMR Shareholding
7th Feb 20221:52 pmRNSDirector/PDMR Shareholding
7th Feb 20221:50 pmRNSDirector/PDMR Shareholding
7th Feb 20221:48 pmRNSDirector/PDMR Shareholding
7th Feb 20221:47 pmRNSDirector/PDMR Shareholding
7th Feb 20221:46 pmRNSDirector/PDMR Shareholding
7th Feb 202210:50 amRNSIssue of Equity
4th Feb 20229:45 amRNSStatement re NAV and Final Dividend
31st Jan 20224:25 pmRNSStatement re Offer for Subscription
10th Jan 202212:43 pmRNSStatement re Offer for Subscription
5th Jan 202210:35 amRNSDividend Declaration
24th Nov 20214:45 pmRNSTransaction in Own Shares
29th Oct 202112:44 pmRNSNet Asset Value(s)
20th Oct 20214:46 pmRNSResult of General Meeting
20th Sep 20215:21 pmRNSPublication of a Prospectus
20th Sep 20214:57 pmRNSStatement re Change of Registrar
10th Sep 202112:34 pmRNSIssue of Equity
7th Sep 20213:08 pmRNSStatement re Dividend Investment Scheme
16th Aug 20214:08 pmRNSTransaction in Own Shares
13th Aug 20212:13 pmRNSHalf-year Report
5th Aug 20214:39 pmRNSTransaction in Own Shares
3rd Aug 202111:31 amRNSStatement re NAV and Interim Dividend
16th Jun 20213:16 pmRNSStatement re Offer for Subscription
16th Apr 202110:25 amRNSIssue of Equity
15th Apr 20214:30 pmRNSTransaction in Own Shares
13th Apr 20212:22 pmRNSStatement re Dividend Investment Scheme
12th Apr 20219:00 amRNSNet Asset Value(s)
7th Apr 202112:28 pmRNSResult of AGM
5th Mar 20214:39 pmRNSFinal Results
29th Jan 20212:55 pmRNSTransaction in Own Shares
22nd Jan 20213:17 pmRNSNAV and Proposed Final Dividend
17th Nov 20204:29 pmRNSTransaction in Own Shares
16th Nov 20204:55 pmRNSTransaction in Own Shares
11th Nov 20204:58 pmRNSNet Asset Value(s)
28th Aug 202010:28 amRNSIssue of Equity
26th Aug 20205:23 pmRNSTransaction in Own Shares
21st Aug 20204:10 pmRNSStatement re NAV and DIS
29th Jul 20204:45 pmRNSTransaction in Own Shares
28th Jul 20204:44 pmRNSTransaction in Own Shares
24th Jul 20203:23 pmRNSHalf-year Report
9th Jul 202010:00 amRNSIssue of Equity
29th Jun 20205:25 pmRNSStatement re NAV and Interim Dividend
8th Jun 20209:33 amRNSAllotment Update
15th May 20204:55 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.